Alzamend Neuro Inc (ALZN) Stock Analysis

What Alzamend Neuro Inc does

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Key metrics

ETFs linked to ALZN

Broad-market and Healthcare sector ETFs an investor holding Alzamend Neuro Inc is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ALZN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Alzamend Neuro Inc?

Alzamend Neuro Inc trades under the ticker ALZN on NASDAQ.

Which exchange is ALZN listed on?

ALZN is listed on NASDAQ.

What sector does Alzamend Neuro Inc operate in?

Alzamend Neuro Inc is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ALZN in a portfolio?

PortView shows ALZN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.